Abstract

Alzheimer’s disease (AD) remains a significant public health challenge, with an increasing prevalence worldwide. Despite extensive research, effective treatment options remain limited. However, recent advancements in clinical trials and drug development have led to the emergence of promising therapeutic agents. This review examines the latest treatments for AD, focusing on disease-modifying therapies (DMTs), monoclonal antibodies targeting amyloid-beta, taubased treatments, and novel small molecules. It highlights key clinical trials, regulatory approvals, and their implications for patient care. The review also discusses challenges in drug development, including safety concerns, efficacy limitations, and accessibility issues. Recent FDA approvals of aducanumab and lecanemab have ignited hope for modifying disease progression, yet controversy remains regarding their clinical benefits. Emerging non-pharmacological approaches, such as gene therapy and neurostimulation, also show potential. This review provides a comprehensive overview of current advancements and their impact on future AD treatment strategies.